Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Naftifine
Drug ID BADD_D01517
Description Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.
Indications and Usage For the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.
Marketing Status approved
ATC Code D01AE22
DrugBank ID DB00735
KEGG ID D08245
MeSH ID C029178
PubChem ID 47641
TTD Drug ID D00HPK
NDC Product Code Not Available
UNII 4FB1TON47A
Synonyms naftifine | naftifin | naftifine hydrochloride, (E)-isomer | naftifine hydrochloride | N-cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride
Chemical Information
Molecular Formula C21H21N
CAS Registry Number 65472-88-0
SMILES CN(CC=CC1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agranulocytosis01.02.03.001--Not Available
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.0010.003757%Not Available
Application site pruritus12.07.01.005; 08.02.01.005; 23.03.12.0040.003757%Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.0160.003757%Not Available
Application site reaction12.07.01.006; 08.02.01.0060.003757%Not Available
Blister23.03.01.001; 12.01.06.0020.024420%Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.0030.005635%Not Available
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Erythema23.03.06.0010.011271%Not Available
Headache17.14.01.001--
Hypersensitivity10.01.03.0030.011271%
Leukopenia01.02.02.001--Not Available
Pain08.01.08.004--
Pain of skin23.03.03.003--
Pruritus23.03.12.0010.006188%
Rash23.03.13.0010.011271%Not Available
Scab23.03.03.0040.002431%Not Available
Skin exfoliation23.03.07.0030.015580%Not Available
Swelling08.01.03.015--Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.003757%Not Available
Application site papules23.03.03.022; 12.07.01.025; 08.02.01.0250.003757%Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
The 1th Page    1    Total 1 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene